论文部分内容阅读
目的：研究与分析肝癌细胞株经阿霉素与索拉菲尼处理后对HepG2的抑制作用及机制。方法按照药物使用情况分为索拉菲尼组(甲组)、阿霉素组(乙组)、阿霉素联合索拉菲尼组(丙组)；并分别作用于肝细胞株HepG2细胞。并分析与比较三组细胞增殖抑制及细胞凋亡等情况。结果三组均可有效抑制HepG2细胞增殖，且存在剂量依赖性；但丙组具有协同效应(<0.05)。甲、乙组均可使HepG2细胞周期停滞于G0-G1期；但丙组G0/G1期细胞比率明显低于甲乙两组；且S期明显高于甲乙两组(P<0.05)。三组均可诱导HepG2细胞凋亡，但丙组更加显著(<0.05)；乙组可有效抑制HepG2细胞Survivin mRNA表达诱导细胞的凋亡。结论阿霉素联合索拉菲尼对肝癌细胞株HepG2具有较好协同效果，同时还可加速细胞增殖抑制，从而起到抑制肿瘤细胞生长效果。因此，临床可进一步研究，以更好地为肝癌临床治疗提供参考依据，从而改善患者预后。“,”Objective Research and Analysis of hepatoma cel lines by doxorubicin treated with sorafenib and mechanism of inhibition of HepG2.Methods According to drug use into sorafenib group (Group A),doxorubicin group (Group B),doxorubicin combined with sorafenib group (Group C);and acts on the liver cel line HepG2 cel s,respectively.Analysis and comparison of the three groups and inhibition of cel proliferation and apoptosis and so on.Results Three groups can ef ectively inhibit the proliferation of HepG2 cel s in a dose-dependent manner;but Group C has a synergistic ef ect( <0.05).A,B can make HepG2 cel cycle ar est in G0-G1 phase;but Group C G0/G1 phase of the cel ratio was significantly lower than the A and B groups;was significantly higher than that of B and S groups ( <0.05).Three groups can induce apoptosis in HepG2 cel s,but Group C is more significant ( <0.05);B can ef ectively inhibit Survivin mRNA expression in HepG2 cel apoptosis induced cel s. Conclusion Doxorubicin combined with sorafenib for hepatocel ular carcinoma cel line HepG2 has good synergistic ef ect,but can also accelerate cel proliferation,thereby restrain the growth ef ect of tumor cel s.Therefore,further clinical studies to bet er provide reference for clinical treatment of liver cancer,thereby improving patient outcomes.